Pasithea Therapeutics (KTTA) Cash & Equivalents (2021 - 2024)
Historic Cash & Equivalents for Pasithea Therapeutics (KTTA) over the last 4 years, with Q3 2024 value amounting to $9.4 million.
- Pasithea Therapeutics' Cash & Equivalents fell 5223.89% to $9.4 million in Q3 2024 from the same period last year, while for Sep 2024 it was $9.4 million, marking a year-over-year decrease of 5223.89%. This contributed to the annual value of $16.3 million for FY2023, which is 5064.34% down from last year.
- Pasithea Therapeutics' Cash & Equivalents amounted to $9.4 million in Q3 2024, which was down 5223.89% from $8.0 million recorded in Q2 2024.
- Pasithea Therapeutics' 5-year Cash & Equivalents high stood at $53.0 million for Q4 2021, and its period low was $8.0 million during Q2 2024.
- Its 4-year average for Cash & Equivalents is $28.4 million, with a median of $26.6 million in 2023.
- As far as peak fluctuations go, Pasithea Therapeutics' Cash & Equivalents skyrocketed by 10616.38% in 2022, and later tumbled by 6997.86% in 2024.
- Quarter analysis of 4 years shows Pasithea Therapeutics' Cash & Equivalents stood at $53.0 million in 2021, then crashed by 37.53% to $33.1 million in 2022, then plummeted by 50.64% to $16.3 million in 2023, then plummeted by 42.68% to $9.4 million in 2024.
- Its Cash & Equivalents stands at $9.4 million for Q3 2024, versus $8.0 million for Q2 2024 and $12.0 million for Q1 2024.